My ePortfolio Register   
 

Abstract | Full HTML Article | PDF | Portuguese ecancer 10 681 / DOI: 10.3332/ecancer.2016.681

Policy

Phosphoethanolamine and the danger of unproven drugs

The use of unproven forms of therapy in cancer treatment is very common. In Brazil, the distribution by researchers to patients of an investigational agent called phophoethanolamine (PHOS) has led to a widely publicized scientific scandal. PHOS is a precursor to components of the cell membrane, with some published pre-clinical studies suggesting cytotoxic activity in cancer cells. The willingness of courts and of legislators to guarantee access to PHOS in spite of the lack of any clinical data and against the recommendations of scientific and medical organisations underscores the risks that unproven agents pose to regulatory authorities, health care systems and patients, and bears resemblance to other cases such as the controversy surrounding the approval of zidovudine for AIDS treatment by the FDA.

Keywords: phosphoethanolamine, cancer, science, Brazil, ethics

Loading Article Metrics ... Please wait

Related articles

Special Issue: The molecular understanding of cancer: from the unspeakable illness to a curable disease

Abstract | Full Article | PDF Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.747

Special Issue: The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches

Abstract | Full Article | PDF Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.746

Special Issue: Radioguided localisation of non-palpable lesions of the breast in Costa Rica: Review of results of our first 800 patients in private practice

Abstract | Full Article | PDF | Spanish Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.745

Review: Bringing a humanistic approach to cancer clinical trials

Abstract | Full Article | PDF Published: 18 May 2017 / DOI: 10.3332/ecancer.2017.738

Review: Tobacco in post-conflict settings: the case of Iraq

Abstract | Full Article | PDF Published: 28 Apr 2017 / DOI: 10.3332/ecancer.2017.735



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence